Not Yet RecruitingPhase 2ACTRN12606000444583

Polidocanol sclerotherapy of pharyngx for obstructive sleep apnea (OSA) and snoring subjects(SS)

Preliminary study on submucosous sclerosis of pharyngx with 1% polidocanol to treat obstructive sleep apnea (OSA) & snoring subjects (SS)

Sponsor

Youliang Yin

Enrollment

30 participants

Start Date

Dec 1, 2006

Study Type

Interventional

Conditions

Obstructive sleep apnea syndrome (OSAS)Snoring subjects (SS)

Summary

The aim of this prospective study is to evaluate the results of polidocanol sclerotherapy of pharynx for OSAS & SS,to reduce pharyngeal compliance.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 65 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests whether injecting polidocanol (a sclerosing agent) into the throat tissue can reduce obstructive sleep apnea and snoring. Adults ages 18 to 65 whose sleep apnea or snoring is caused by throat tissue collapse (palatopharyngeal collapse) can participate in the treatment sessions.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Polysomnography (PSG) and 1% Polidocanol--submucosous sclerosis in the part of pharyngx with 1% polidocanol injection The duration : about 4~5 years Each patient with OSAS will be followed up 2 year

Polysomnography (PSG) and 1% Polidocanol--submucosous sclerosis in the part of pharyngx with 1% polidocanol injection The duration : about 4~5 years Each patient with OSAS will be followed up 2 years after treatment. The injection administered is during the treatment, the injection should be in the retrophargngeal submucosa and lateral pharyngeal bands and lateral pharyngeal submucosa and in front submucosa of soft palate. The injection is multi-point, and each point injection is 0.3~0.5ml, the total quantity/each time is not more than 5ml; Every patient have to be treated about 1~2 times. -------The duration of the study is 4~5 years.the treatment is only during 1~3 months.The follow-up-2-year is carried on polysomnography and clinical study-observarion.

Locations(1)

China

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12606000444583